Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Crowe

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
ANZ Journal of Surgery|June 21, 2002
Trade-offs: survival versus morbidity in breast cancerPhilip J Crowe
Journal of Surgical Oncology|February 27, 2007
Targeted therapies in adult soft tissue sarcomasJia-Lin Yang, Philip J Crowe
ANZ Journal of Surgery|June 14, 2006
Does presentation at the Registrars' Papers Day predict future publication?Shing W Wong, Philip J Crowe
ANZ Journal of Surgery|December 1, 2010
Exploring Australasian surgical trainees' satisfaction with operating theatre learning using the 'surgical theatre educational environment measure'Adam Mahoney, Philip J Crowe, Peter Harris
Journal of Cancer Research and Clinical Oncology|February 9, 2010
Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involvedAlyse Hopkins, Philip J Crowe, Jia-Lin Yang
Journal of Cancer Research and Clinical Oncology|June 18, 2009
Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugsBeata Zahorowska, Philip J Crowe, Jia-Lin Yang
Journal of Surgical Oncology|April 8, 2011
Trends in surgical oncology research in Australia during the period 1998-2009--a bibliometric reviewTerence C Chua, Philip J Crowe, David L Morris
ANZ Journal of Surgery|October 26, 2011
Whither surgical oncology?Terence C Chua, Philip J Crowe, David L Morris
International Journal of Oncology|April 6, 2018
Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell linesXiaochun Wang, David Goldstein, Philip J Crowe, et al.
Oncotargets and Therapy|September 24, 2016
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceXiaochun Wang, David Goldstein, Philip J Crowe, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
ANZ Journal of Surgery|June 21, 2002
Trade-offs: survival versus morbidity in breast cancerPhilip J Crowe
Journal of Surgical Oncology|February 27, 2007
Targeted therapies in adult soft tissue sarcomasJia-Lin Yang, Philip J Crowe
ANZ Journal of Surgery|June 14, 2006
Does presentation at the Registrars' Papers Day predict future publication?Shing W Wong, Philip J Crowe
ANZ Journal of Surgery|December 1, 2010
Exploring Australasian surgical trainees' satisfaction with operating theatre learning using the 'surgical theatre educational environment measure'Adam Mahoney, Philip J Crowe, Peter Harris
Journal of Cancer Research and Clinical Oncology|February 9, 2010
Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involvedAlyse Hopkins, Philip J Crowe, Jia-Lin Yang
Journal of Cancer Research and Clinical Oncology|June 18, 2009
Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugsBeata Zahorowska, Philip J Crowe, Jia-Lin Yang
Journal of Surgical Oncology|April 8, 2011
Trends in surgical oncology research in Australia during the period 1998-2009--a bibliometric reviewTerence C Chua, Philip J Crowe, David L Morris
ANZ Journal of Surgery|October 26, 2011
Whither surgical oncology?Terence C Chua, Philip J Crowe, David L Morris
International Journal of Oncology|April 6, 2018
Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell linesXiaochun Wang, David Goldstein, Philip J Crowe, et al.
Oncotargets and Therapy|September 24, 2016
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceXiaochun Wang, David Goldstein, Philip J Crowe, et al.
Pageof 4